HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Lowers Price Target to $13
HC Wainwright & Co. Maintains Buy on Aurinia Pharmaceuticals, Lowers Price Target to $13
HC Wainwright & Co.維持對Aurinia製藥的買入，將目標股價下調至13美元
HC Wainwright & Co. analyst Ed Arce maintains Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy and lowers the price target from $15 to $13.
HC Wainwright & Co. 分析師埃德·阿爾塞維持Aurinia Pharmicals（納斯達克股票代碼：AUPH）的買入並將目標股價從15美元下調至13美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。